Adjuvant Glycerol is Not Beneficial in Experimental Pneumococcal Meningitis

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2010 Apr 1

PMID 20353584

Citations 6

Authors

Cornelia Blaser

Matthias Klein

Denis Grandgirard

Matthias Wittwer

Heikki Peltola

Michael Weigand

Uwe Koedel

Stephen L Leib

Affiliations

Soon will be listed here.

Abstract

Background: Bacterial meningitis in children causes high rates of mortality and morbidity. In a recent clinical trial, oral glycerol significantly reduced severe neurological sequelae in paediatric meningitis caused by Haemophilus influenzae type b, and a tendency towards a benefit of adjunctive glycerol was seen in pneumococcal meningitis.

Methods: Here we examined the effects of glycerol in pneumococcal meningitis of infant rats and adult mice. All animals received ceftriaxone, and glycerol or placebo. Brain damage, hearing loss, and inflammatory parameters were assessed.

Results: Clinically and by histopathology, animals treated with glycerol or placebo did not differ. While both groups showed equally high levels of matrix metalloproteinase-9 at 24 h after infection, a significant difference in favour of glycerol was observed at 40 h after infection. However, this difference in matrix metalloproteinase-9 in late disease did not result in an improvement of histopathologic parameters.

Conclusion: No benefit of adjunctive glycerol was found in these models of pneumococcal meningitis.

Citing Articles

Osmotic therapies added to antibiotics for acute bacterial meningitis.

Wall E, Ajdukiewicz K, Bergman H, Heyderman R, Garner P Cochrane Database Syst Rev. 2018; 2:CD008806.

PMID: 29405037 PMC: 5815491. DOI: 10.1002/14651858.CD008806.pub3.

Meta-analysis of studies comparing adjuvant dexamethasone to glycerol to improve clinical outcome of bacterial meningitis.

Vaziri S, Mansouri F, Sayad B, Ghadiri K, Torkashvand E, Rezaei M J Res Med Sci. 2016; 21:22.

PMID: 27904568 PMC: 5122109. DOI: 10.4103/1735-1995.179890.

Preventive Ceftriaxone in Patients with Stroke Treated with Intravenous Thrombolysis: Post Hoc Analysis of the Preventive Antibiotics in Stroke Study.

Vermeij J, Westendorp W, Roos Y, Brouwer M, van de Beek D, Nederkoorn P Cerebrovasc Dis. 2016; 42(5-6):361-369.

PMID: 27336314 PMC: 5296924. DOI: 10.1159/000446160.

Osmotic therapies added to antibiotics for acute bacterial meningitis.

Wall E, Ajdukiewicz K, Heyderman R, Garner P Cochrane Database Syst Rev. 2013; (3):CD008806.

PMID: 23543568 PMC: 3996551. DOI: 10.1002/14651858.CD008806.pub2.

Use of corticosteroids and other adjunct therapies for acute bacterial meningitis in adults.

Prasad K, Rai N, Kumar A Curr Infect Dis Rep. 2012; 14(4):445-53.

PMID: 22678778 DOI: 10.1007/s11908-012-0271-7.

References

Paul R, Lorenzl S, Koedel U, Sporer B, Vogel U, Frosch M . Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann Neurol. 1998; 44(4):592-600. DOI: 10.1002/ana.410440404. View

Sankar J, Singhi P, Bansal A, Ray P, Singhi S . Role of dexamethasone and oral glycerol in reducing hearing and neurological sequelae in children with bacterial meningitis. Indian Pediatr. 2007; 44(9):649-56. View

Klein M, Paul R, Angele B, Popp B, Pfister H, Koedel U . Protein expression pattern in experimental pneumococcal meningitis. Microbes Infect. 2006; 8(4):974-83. DOI: 10.1016/j.micinf.2005.10.013. View

Peltola H, Roine I, Fernandez J, Zavala I, Gonzalez Ayala S, Gonzalez Mata A . Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2007; 45(10):1277-86. DOI: 10.1086/522534. View

Leib S, Clements J, Lindberg R, Heimgartner C, Loeffler J, Pfister L . Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain. 2001; 124(Pt 9):1734-42. DOI: 10.1093/brain/124.9.1734. View

Kieseier B, Paul R, Koedel U, Seifert T, Clements J, Gearing A . Differential expression of matrix metalloproteinases in bacterial meningitis. Brain. 1999; 122 ( Pt 8):1579-87. DOI: 10.1093/brain/122.8.1579. View

Schmidt H, Stuertz K, Chen V, Stringaris A, Bruck W, Nau R . Glycerol does not reduce neuronal damage in experimental Streptococcus pneumoniae meningitis in rabbits. Inflammopharmacology. 2007; 6(1):19-26. DOI: 10.1007/s10787-998-0003-7. View

Leppert D, Leib S, Grygar C, Miller K, Schaad U, Hollander G . Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. Clin Infect Dis. 2000; 31(1):80-4. DOI: 10.1086/313922. View

Galiza E, Heath P . Improving the outcome of neonatal meningitis. Curr Opin Infect Dis. 2009; 22(3):229-34. DOI: 10.1097/QCO.0b013e32832ad49e. View

10.

Peltola H, Roine I . Improving the outcomes in children with bacterial meningitis. Curr Opin Infect Dis. 2009; 22(3):250-5. DOI: 10.1097/QCO.0b013e328329c47a. View

11.

Klein M, Schmidt C, Kastenbauer S, Paul R, Kirschning C, Wagner H . MyD88-dependent immune response contributes to hearing loss in experimental pneumococcal meningitis. J Infect Dis. 2007; 195(8):1189-93. DOI: 10.1086/512859. View

12.

Kilpi T, Peltola H, Jauhiainen T, Kallio M . Oral glycerol and intravenous dexamethasone in preventing neurologic and audiologic sequelae of childhood bacterial meningitis. The Finnish Study Group. Pediatr Infect Dis J. 1995; 14(4):270-8. DOI: 10.1097/00006454-199504000-00005. View

13.

Grandgirard D, Schurch C, Cottagnoud P, Leib S . Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob Agents Chemother. 2007; 51(6):2173-8. PMC: 1891377. DOI: 10.1128/AAC.01014-06. View

14.

Leib S, Leppert D, Clements J, Tauber M . Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun. 2000; 68(2):615-20. PMC: 97183. DOI: 10.1128/IAI.68.2.615-620.2000. View